

April 5, 2019



# Codexis Senior Vice President of R&D Dr. Jim Lalonde Announces Plan to Resign

REDWOOD CITY, Calif., April 05, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that Jim Lalonde, Ph.D., Senior Vice President of Research and Development, will resign effective May 31, 2019 to pursue other interests.

“Jim has played an integral role over many years with the Codexis team refining and applying our CodeEvolver<sup>®</sup> protein engineering platform. We thank him for his many contributions to the success of our company and wish him well in his future endeavors,” said John Nicols, Codexis President and Chief Executive Officer. “With a deeply experienced and long-tenured leadership team under Jim, we have full confidence in the seamless continuity of our R&D function. Succession plans are in motion to ensure that Codexis is setup for the next chapter of technology advancements and stepout growth applying the CodeEvolver<sup>®</sup> protein engineering platform.”

“I am extremely grateful to all of the past and present scientists at Codexis. It has been a privilege to collaborate with such talented professionals, and to have helped drive the CodeEvolver<sup>®</sup> protein engineering platform to deliver sustainable solutions to a growing number of industries,” said Dr. Lalonde. “I am very proud of the R&D team assembled at Codexis, and am confident all ongoing and planned programs are in capable hands.”

## About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver<sup>®</sup> technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see [www.codexis.com](http://www.codexis.com)

## Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 9, 2019 under the caption

“Risk Factors” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law..

**Investors**

LHA Investor Relations  
Jody Cain, 310-691-7100  
jcain@lhai.com



Source: Codexis, Inc.